Please assess the completion status of the following clinical trial:

Trial Title: Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. T2DM patients and healthy controls aged =18 to \<70 at Visit 1.~2. Patients diagnosed with T2DM according to the American Diabetes Association criteria prior to informed consent who are drug-naïve~3. T2DM patients on a stable dose of allowed concomitant medications (as determined by investigator) for 30 days prior to entering the study.~4. T2DM patients with HbA1c between \>7 and \<10.0% (\>53 mmol/mol and \<86 mmol/mol) at Visit~Exclusion criteria:~1. Patients with type 1 diabetes mellitus.~2. Patients with uncontrolled hyperglycemia with a fasting plasma glucose level greater than 240 mg/dl after an overnight fast.~3. Patients with a history of clinically significant heart disease (New York Heart Classification greater than class 3; more than non-specific ST-T wave changes on the ECG), peripheral vascular disease (history of claudication), or pulmonary disease as determined by investigator.~4. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Controls (Type: EXPERIMENTAL): healthy controls
- Patients (Type: EXPERIMENTAL): patients with type 2 diabetes mellitus

Based on this trial design, predict the completion outcome and termination type (if applicable).